Boston, United States
Paratus Sciences, founded in 2021 and headquartered in the United States, is positioned at the intersection of Biotechnology and Health Care. The company aims to harness the unique evolutionary biology of bats to develop advanced therapeutics for humans, as encapsulated in their slogan, "Revealing bats' evolutionary edge for better human therapeutics."
Leveraging a proprietary platform integrating cell biology, genomics, and informatics, Paratus Sciences compares bats' disease-resistance mechanisms with human disease patterns. Their initial pipeline focuses on immunology, inflammation, and cardiometabolism, with potential expansions into oncology and aging. Collaborative efforts with the National Institute of Allergy and Infectious Disease indicate promising virology applications.
Strong financial backing underscores market confidence, with a recent $100 million Series A investment led by renowned names such as ARCH Venture Partners, Polaris Partners, and EcoR1 Capital. This support highlights the company's potential to leverage bats' biology into breakthroughs in human therapeutics.
